Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.

Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is ...

Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...

Hyderabad: In a major strategic move, Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Aurobindo ...

The deal is being carried out on a cash-free, debt-free basis, factoring in standardised working capital levels.

The transaction is valued at an enterprise value of $250 million (₹21,850 crore) on a cash-free, debt-free basis, including ...

Aurobindo Pharma USA acquires Lannett Company LLC for $250 million, expanding U.S. manufacturing capabilities and product ...

TREVOSE, Pa., May 2, 2023 /PRNewswire/ -- Lannett Company, Inc. (OTCMKTS: LCIN) (the "Company" or "Lannett") today announced that it and certain of its subsidiaries have commenced prepackaged ...

--Lannett Company, Inc. today announced that it and certain of its subsidiaries have commenced prepackaged Chapter 11 cases in the United States Bankruptcy Court for the District of Delaware to ...

About Lannett Company, Inc.: Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

By Lannett Company, Inc. Restructuring Support Agreement Supported by Holders of More Than 80% of the Company's Senior Secured Notes and 100% of the Company's Second Lien Term Loans Transaction ...